Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Active Trials
    2(67%)

    Phase Distribution

    Phase 2
    1
    33%
    Phase 3
    1
    33%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    1

    Late Stage

    Phase Distribution2 total trials
    Phase 2Efficacy & side effects
    1(50.0%)
    Phase 3Large-scale testing
    1(50.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 0 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    2

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Active(2)
    Other(1)

    Detailed Status

    Recruiting2
    unknown1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    2
    Success Rate
    N/A
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 21 (50.0%)
    Phase 31 (50.0%)

    Trials by Status

    unknown133%
    recruiting267%

    Recent Activity

    2 active trials
    Showing 3 of 3
    recruitingphase_3

    Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

    NCT06625970
    recruitingphase_2

    The University of Miami Adapt (UAdapt) Trial

    NCT06111313
    unknown

    An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

    NCT03523338

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT06625970Phase 3

    Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

    Recruiting
    NCT06111313Phase 2

    The University of Miami Adapt (UAdapt) Trial

    Recruiting
    NCT03523338

    An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

    Unknown

    All 3 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    3